Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe.

Autor:	Moreno-Martos D; Population Health and Genomics, University of Dundee, Dundee, UK., Verhamme K; Medical Informatics, Erasmus MC, Rotterdam, The Netherlands., Ostropolets A; Biomedical Informatics, Columbia University Medical Center, New York, USA., Kostka K; Real World Solutions, IQVIA, Cambridge, MA, USA.; OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA., Duarte-Sales T; Fundació Institut Universitari per a la recerca a l'Atenció Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), IDIAPJGol, Barcelona, Spain., Prieto-Alhambra D; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Alshammari TM; College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia., Alghoul H; Faculty of Medicine, Islamic University of Gaza, Gaza, Palestinian Territory., Ahmed WU; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.; College of Medicine and Health, University of Exeter, Exeter, UK., Blacketer C; Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.; Janssen Research and Development, Janssen Research and Development, Titusville, NJ, USA., DuVall S; VA Informatics and Computing Infrastructure, University of Utah, Salt Lake City, UT, USA., Lai L; Department of Medical Sciences, University of Manchester, Manchester, UK., Matheny M; Geriatrics Research Education and Clinical Care Service & VINCI, Tennessee Valley Healthcare System VA, nashville, TN, USA.; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA., Nyberg F; School of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden., Posada J; Department of Medicine, Stanford University, Redwood City, CA, USA., Rijnbeek P; Medical Informatics, Erasmus MC, Rotterdam, The Netherlands., Spotnitz M; Biomedical Informatics, Columbia University Medical Center, New York, USA., Sena A; Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.; Janssen Research and Development, Janssen Research and Development, Titusville, NJ, USA., Shah N; Department of Medicine, Stanford University, Redwood City, CA, USA., Suchard M; Department of Biostatistics UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Computational Medicine David Geffen School of Medicine at UCLA,, University of California, Los Angeles, Los Angeles, CA, USA., Chan You S; Department of Preventive Medicine, Yonsei University, Seoul, South Korea., Hripcsak G; Biomedical Informatics, Columbia University Medical Center, New York, USA., Ryan P; Biomedical Informatics, Columbia University Medical Center, New York, USA.; Janssen Research and Development, Janssen Research and Development, Titusville, NJ, USA., Morales D; Population Health and Genomics, University of Dundee, Dundee, UK.; Department of Public Health, University of Southern Denmark, Odense, Denmark.
Jazyk:	angličtina
Zdroj:	Wellcome open research [Wellcome Open Res] 2023 Jan 10; Vol. 7, pp. 22. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2022).
DOI:	10.12688/wellcomeopenres.17403.3
Abstrakt:	Background : Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods : We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results : The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients.   Conclusion : COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes. Competing Interests: Competing interests: Dr. Verhamme works for a research department who received/receives unconditional research grants from Pfizer/Boehringer Ingelheim, Yamanouchi, Novartis, GSK, Chiesi, Amgen, UCB, J&J none of which are related to the content of this work; Ms. Kostka reports consulting fees from National Institutes of Health NCATS, outside the submitted work; and during the 36 months prior to publication, Ms. Kostka was an employee of IQVIA Inc (a commercial entity); Dr. Prieto-Alhambra reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants; Dr. Blacketer reports and full-time employee of Janssen R&D and a stockholder of Johnson & Johnson; Dr. DuVall reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Veteran Research, outside the submitted work; Dr. Nyberg reports other from AstraZeneca, outside the submitted work; Dr. Posada reports grants from National Library of Medicine, during the conduct of the study; Dr. Rijnbeek reports grants from Innovative Medicines Initiative, from Janssen Research and Development, during the conduct of the study; Dr. Sena reports and full-time employee of Janssen R&D and a stockholder of Johnson & Johnson; Dr. Shah reports grants from National Library of Medicine, during the conduct of the study; Dr. Suchard reports grants from US National Institutes of Health, grants from US Department of Veterans Affairs, during the conduct of the study; grants from US Food & Drug Administration, personal fees from Janssen Research & Development, outside the submitted work; Dr. Hripcsak reports grants from US National Institutes of Health, during the conduct of the study; grants from Janssen Research, outside the submitted work; Dr. Ryan reports and is employee of Janssen Research and Development and shareholder of Johnson & Johnson; Dr. Morales is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), and Tenovus outside the submitted work. (Copyright: © 2023 Moreno-Martos D et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu